In a safety communication released September 7, 2011, FDA announced it is requiring the prescribing information for all tumor necrosis factor-alpha blockers to include a black-boxed warning regarding an increased risk of infection from 2 bacterial pathogens, Legionella and Listeria.
In a safety communication released September 7, 2011, FDA announced it is requiring the prescribing information for all tumor necrosis factor (TNF)-alpha blockers to include a black-boxed warning regarding an increased risk of infection from 2 bacterial pathogens, Legionella and Listeria. Each of these biologic agents suppress patients' immune systems, and consequently, increase the risk of serious and potentially fatal bacterial, mycobacterial, fungal, parasitic, and viral infections.
Currently, a number of TNF-alpha blockers have marketing approval in the United States including infliximab (Remicade), etanercept (Enbrel), adalimumab (Humira), certolizumab pegol (Cimzia), and golimumab (Simponi). These agents are approved for a host of different indications such as Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, and juvenile idiopathic arthritis. The first of these agents was approved by FDA back in 1998.
The decision to include Legionella infection in the prescribing information of TNF-alpha blockers comes after FDA's review of the Adverse Event Reporting System (AERS) database through 2010. The agency's search identified 80 reports of patients developing Legionella pneumonia (30 of which were confirmed by laboratory analysis) after receiving a TNF-alpha inhibitor. Fourteen of these cases were ultimately fatal. Patients developing Legionella were between 25 and 85 years of age, 65% had a diagnosis of rheumatoid arthritis, and the median duration of TNF-alpha blocker administration prior to onset of Legionella infection was about 10 months. Of note, many of these patients were receiving concomitant immunosuppressant therapy. FDA also identified published case reports describing an additional 23 cases of Legionella pneumonia resulting from TNF-alpha blocker use.
Along with these new warnings, agency officials are recommending prescribers weigh both the risks and the benefits of TNF-alpha blockers prior to initiating therapy; particularly in patients with chronic or recurrent infection and in patients with underlying conditions that may predispose them to infection. FDA also suggests patients be monitored closely for signs and symptoms of serious infections while on therapy.
SOURCE
FDA. FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria [Posted 09/7/2011]. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm. Accessed September 17, 2011.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.